Erratum: Pathology consultation on anticoagulation monitoring: factor X–related assays (American Journal of Clinical Pathology (2013) 140 (623-634) DOI: 10.1309/AJCPR3JTOK7NKDBJ);Pathology consultation on anticoagulation monitoring: Factor X-related assays

American Journal of Clinical Pathology

Volumn 140, Issue 5, 2013, Pages 623-634

  Wool, Geoffrey D ^a   Lu, Chuanyi M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Anticoagulation monitoring; Chromogenic anti Xa assay; Chromogenic factor X activity assay; Direct factor Xa inhibitor; Direct thrombin inhibitor; Factor X; Heparin; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; CHROMOGENIC SUBSTRATE; DALTEPARIN; ENOXAPARIN; FIBRINOGEN; FONDAPARINUX; HEPARIN; HIRULOG; KALLIKREIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PROTAMINE; PROTHROMBIN; RIVAROXABAN; THROMBIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONSULTATION; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DETERMINATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG MISUSE; DRUG MONITORING; DRUG USE; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LABORATORY TEST; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LUNG EMBOLISM; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OBESITY; OSTEOARTHRITIS; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOEMBOLISM; THROMBOPLASTIN TIME; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VITAMIN K DEFICIENCY;

EID: 84886295541     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPES0BIZ3IVJKW     Document Type: Erratum

References (62)

1. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23:17-25.
2. Graham JB, Barrow EM, Hougie C. Stuart clotting defect: II, genetic aspects of "a new" hemorrhagic state. J Clin Invest. 1956;36:497-503.
3. Girolami A, Scarparo P, Scandellari R, et al. Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation. Am J Hematol. 2008;83:668-671.
4. Colman RW et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA; Lippincott Williams & Wilkin; 2001.
5. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
6. Messmore HL, Fareed J, Kniffin J, et al. Synthetic substrate assays of the coagulation enzymes and their inhibitors: comparison with clotting and immunologic methods for clinical and experimental usage. Ann NY Acad Sci. 1981;370:785-797.
7. Fareed J, Messmore HL, Bermes EW. New perspectives in coagulation testing. Clin Chem. 1980;26:1380-1391.
8. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res. 1976;8:413-416.
9. Ciavarella N, Coccheri S, Gensini GF, et al. Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulant. Thromb Res. 1980;19:493-502.
10. Egberg N, Heedman PA. Simplified performance of amidolytic factor X assay. Thromb Res. 1982;25:437-440.
11. Stief TW. Innovative tests of plasmatic hemostasis. Lab Med. 2008;39:225-230.
12. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324-327.
13. Hirsch J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:188S-203S.
14. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed-American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S-e43S.
15. Lehman CM, Frank EL. Laboratory monitoring of heparin therapy: partial thromboplastin time or anti-Xa assay? Lab Med. 2009;40:47-51.
16. Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol. 2012;87:194-196.
17. Lehman CM, Rettmann JA, Wilson LW, et al. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol. 2006;126:416-421.
18. Harenberg J, Kramer R, Giese C, et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011;32:267-271.
19. Harenberg J, Erdle S, Marx S, et al. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost. 2012;38:178-184.
20. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973;248:6490-6505.
21. Kitchens S. Problems in laboratory monitoring of heparin dosage. Br J Hematol. 2000;111:397-406.
22. Bates SM, Weitz JI. Coagulation assays. Circulation. 2005;112:e53-e60.
23. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798.
24. Gausman JN, Marlar RA. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy. Am J Clin Pathol. 2011;135:870-876.
25. Long E, Pitfield AF, Kissoon N. Anticoagulation therapy: indications, monitoring, and complications. Pediatr Emerg Care. 2011;27:55-61.
26. Andrew M, Schmidt B. Use of heparin in newborn infants. Semin Thromb Hemost. 1988;14:28-32.
27. Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed-American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e737S-e801S.
28. Kuhle S, Eulmesekian P, Kavanagh B, et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica. 2007;92:554-557.
29. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
30. Takemoto CM, Streiff MB, Shermock KM, et al. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol. 2013;139:450-456.
31. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32:546-558.
32. College of American Pathologists. 2012 Hematology and coagulation laboratory accreditation checklist. Available at www.cap.org.
33. Quader MA, Stump LS, Sumpio BE. Low molecular weight heparins: current use and indications. J Am Coll Surg. 1998;187:641-658.
34. Siguret V, Pautas E, Février M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84:800-804.
35. Laposata M, Green D, Van Cott EM, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807.
36. Harenberg J. Is laboratory monitoring of low-molecularweight heparin therapy necessary? Yes. J Thromb Haemost. 2004;2:547-550.
37. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
38. Funk DM. Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program. 2012;2012:460-465.
39. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):141S-159S.
40. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112:2242-2247.
41. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
42. Tripodi A, Chantarangkul V, Guinet C, et al. The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost. 2011;9:226-228.
43. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263-1271.
44. Rojnuckarin P, Akkawat B, Juntiang J. Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring. Clin Appl Thromb Hemost. 2010;16:313-317.
45. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S-21S.
46. Ansell J, Hirsh J, Dalen JE, et al. Managing oral anticoagulant therapy. Chest. 2001;119:22S-38S.
47. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995;108:231S-246S.
48. Kovacs MJ, Wong A, MacKinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost. 1994;71:727-730.
49. Horellou MH, Aurousseau MH, Boffa MC, et al. Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients. J Med. 1987;18:199-217.
50. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988;72:512-519.
51. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997;127:177-185.
52. Ragni MV, Lewis JH, Spero JA, et al. Factor VII deficiency. Am J Hematol. 1981;10:79-88.
53. Sanfelippo MJ, Zinsmaster W, Scherr DL, et al. Use of chromogenic assay of factor X to accept or reject INR results in warfarin treated patients. Clin Med Res. 2009;7:103-105.
54. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-3691.
55. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Ann Rev Med. 1996;47:533-553.
56. Rosborough TK, Shepherd MF. Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy. 2004;24:838-842.
57. Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3:201-208.
58. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76:638-648.
59. Arpino PA, Demirjian A, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy. 2005;25:157-164.
60. Austin JH, Stearns CR, Winkler AM, et al. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy. Pharmacotherapy. 2012;32:493-501.
61. Osinbowale O, Malki AL, Schade A, et al. An algorithm for managing warfarin resistance. Cleve Clin J Med. 2009;76:724-730.
62. McGlasson DL, Romick BG, Rubal BJ. Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy. Blood Coagul Fibrinolysis. 2008;19:513-517.